Pancreatic Cancer Research

ResearcherColumbia UniversityNo recent work listed

Thomas Ludwig

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3461-2585; OpenAlex author ID A5103195984. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: 3 papers · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper

Papers 8

  1. Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains. Last author DOI 10.1371/journal.pone.0226714↗
  2. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2016-311585↗
  3. Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer. Co-author DOI 10.1038/srep10867↗
  4. Anti-IL-6 and PD-L1 antibody combination therapy reduces tumor progression in murine models of pancreatic cancer Co-author DOI 10.1186/2051-1426-3-s2-p366↗
  5. Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer. Co-author DOI 10.18632/oncotarget.6332↗
  6. BMS-911543 inhibits viability of tumor and stromal cells and limits disease progression in genetically engineered mice with pancreatic cancer Co-author DOI 10.1186/2051-1426-2-s3-p186↗
  7. High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesion… Co-author DOI 10.1158/1078-0432.ccr-12-3020↗
  8. Genetically engineered murine pancreatic cancer models approximate immunophenotypic properties of human patients Co-author DOI 10.1186/2051-1426-1-s1-p163↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thomas A. Mace · 6 shared papers, 2013–2019 · strength 0.32
  2. Tanios Bekaii‐Saab · 6 shared papers, 2013–2018 · strength 0.27
  3. Jason Robert Pitarresi · 4 shared papers, 2015–2019 · strength 0.25
  4. Mark Bloomston · 5 shared papers, 2013–2018 · strength 0.22
  5. Gregory B. Lesinski · 5 shared papers, 2013–2018 · strength 0.22
  6. Michael C. Ostrowski · 4 shared papers, 2013–2018 · strength 0.19
  7. Xiaoling Zhong · 2 shared papers, 2015–2018 · strength 0.11
  8. Teresa A Zimmers · 2 shared papers, 2015–2018 · strength 0.11
  9. Dongju Park · 1 shared paper, 2019 · strength 0.10
  10. Wendy L. Frankel · 2 shared papers, 2013–2014 · strength 0.07
  11. Lianbo Yu · 1 shared paper, 2018 · strength 0.07
  12. Zobeida Cruz‐Monserrate · 1 shared paper, 2018 · strength 0.07
  13. Meredith Ann Morgan · 1 shared paper, 2015 · strength 0.04
  14. Moumita Chatterjee · 1 shared paper, 2015 · strength 0.04
  15. Edgar Ben‐Josef · 1 shared paper, 2015 · strength 0.04
  16. Mark M. Zalupski · 1 shared paper, 2015 · strength 0.04
  17. Terence Marques Williams · 1 shared paper, 2015 · strength 0.04
  18. Ching‐Shih Chen · 1 shared paper, 2015 · strength 0.04
  19. Gazala Naaz Khan · 1 shared paper, 2015 · strength 0.04
  20. Peter Muscarella Md · 1 shared paper, 2014 · strength 0.04
  21. Mitch A. Phelps · 1 shared paper, 2013 · strength 0.03
  22. Timothy D. Eubank · 1 shared paper, 2013 · strength 0.03
  23. Aimee Lee Lucas · 1 shared paper, 2013 · strength 0.03
  24. John A. Chabot · 1 shared paper, 2013 · strength 0.03
  25. Harold Frucht · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.